

A restriction has been required to one of six groups of inventions, characterized as Groups I to VI. The Groups, claims and associated subject matter are as follows.


Group	Claims	Subject Matter
I	1-8, 10-16, 18, 19, 33-37, 39-50, and 52-54	Method of imaging thrombus with compounds that are structurally similar to those of Formula IV
II	1-7, 9-16, 18, 19, 33-36, 38-49, and 51-54	Method of imaging thrombus with compounds that are structurally similar to those of Formula V
III	1-7, 10-16, 18, 19, 33-36, 39-49, and 52-54	Method of imaging thrombus with compounds not encompassed by Groups I and II
IV	17, 20-24, 26-32, and 55-58	Method of imaging pulmonary embolus with compounds that are structurally similar to those of Formula IV
V	17, 20-23, 25-32, and 55-58	Method of imaging pulmonary embolus with compounds that are structurally similar to those of Formula V
VI	17, 20-23, 26-32, and 55-58	Method of imaging pulmonary embolus with compounds not encompassed by Groups IV and V

It is stated in the Office Action that the claims of Group I, II and III are unrelated because of the use of different compounds. It is also stated in the Office Action that the claims of Groups IV, V and VI are unrelated because of the use of different compounds. The Examiner has further required an election of species.¹


¹ Applicant wishes to point out that pursuant to the Examiner's June 20, 2001 Office Action, Applicant was required to elect a species from original Claims 1-19. In a Response dated October 22, 2001, Applicant elected Compound V as set forth on page 25 and also added new Claims 20-58. It is Applicant's understanding that, because of the addition of Claims 20-58, the Examiner has reissued his election of species requirement and has not entered the election from the October 22 Response. If Applicant's understanding is incorrect, thereby precluding the election of a different species, it is respectfully requested that the Examiner advise Applicant accordingly.

Applicant hereby elects for prosecution the subject matter of Group IV (Claims 17, 20-24, 26-32 and 55-58). Applicant wishes to point out, however, that the Examiner's description of the Group is incorrect in that A_{L1} is aminocarboxylate and A_{L2} is trisubstituted phosphines, rather than both A_{L1} and A_{L2} being trisubstituted phosphines.

Applicant hereby elects the species of Compound (IV) on page 25 of formula:




Also, as requested by the Examiner, Applicant characterizes one of the methods of defining the elected species as follows:



(I) ,

wherein,



R^{31} is an aromatic carbocyclic ring system substituted with 1 R^{10} ;

R^{32} is $-C(=O)-$;

n'' is 0;

n' is 1;

R^1 is hydrogen,

R^{13} is selected independently from: H and C1 alkyl;

R^{21} is hydrogen;

R^2 is H;

R^{10} is $-NR^{13}C(=O)R^{13}$;

J is an L-isomer or D-isomer amino acid of structure $-N(R^3)C(R^4)(R^5)C(=O)-$, wherein:

R^3 is H;

R^4 is H;


R^5 is C_3 alkyl;

K is a D-isomer or L-isomer amino acid of structure
 $-N-(R^6)CH(R^7)C(=O)-$, wherein:

R^6 is C_1 alkyl;

R^7 is $-(C_3 \text{ alkyl})X$;

X is selected from:




L is $-Y(CH_2)_vC(=O)-$, wherein:

Y is NH;

$v = 1$ or 2 ;

M is a D-isomer or L-isomer amino acid of structure




wherein:

q' is 1;



R^{17} is H;

d' is 1;

L_n is a linking group of formula:



wherein:



g is 0;

g' is 0;

g'' is 0;

f is 5;

f' is 1;

f'' is 0;

Y¹ is NHC(=O);

Y² is NHC(=O);

R⁵⁵ and R⁵⁶ are independently hydrogen;

M_T is a transition metal radionuclide;

C_h is a radionuclide metal chelator or bonding unit bound to the transition metal radionuclide of formula R⁴⁰R⁴¹N-N= ;

R⁴⁰ is a heterocycle substituted with 1 R⁵²;

R⁴¹ is hydrogen;

R⁵² is a bond to L_n;

A_{L1} is a functionalized aminocarboxylate;

A_{L2} is a trisubstituted phosphine;

x is 1;

y is 1; and

z is 1.


CONCLUSION

Applicant believes that the foregoing constitutes a complete and full response to the Office Action of record. An early and favorable consideration of the present application is respectfully requested.

Please continue to send all correspondence to:

Bristol-Myers Squibb Pharmaceutical Company
P.O. Box 4000
Princeton, New Jersey 08543-4000
Telephone: (302) 467-5260
Facsimile: (302) 467-6701

Respectfully submitted,



Steven D. Maslowski
Registration No. 46,905

Date: July 12, 2002

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100
July 2002